GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Series GSE138415 Query DataSets for GSE138415
Status Public on Jan 11, 2021
Title Peptidylarginine deiminase IV (PADI4) has a novel tumor cell-autonomous suppressor role in regulating breast cancer stem cells [RNA-Seq_1]
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Peptidylarginine deiminases (PADIs) catalyze post-translational modification of many target proteins and have been suggested to play a role in carcinogenesis. Since citrullination of histones by PADI4 was recently implicated in regulating embryonic stem and hematopoietic progenitor cells, here we investigated a possible role for PADI4 in regulating breast cancer stem cells. We showed by genetic and pharmacologic approaches that PADI4 activity limits the number of cancer stem cells (CSCs) in vitro and in vivo in multiple breast cancer models. A gene signature reflecting tumor cell-autonomous PADI4 inhibition is associated with poor outcome in human breast cancer datasets, consistent with a tumor suppressive role for PADI4. Mechanistically, PADI4 inhibition resulted in a global redistribution of histone H3 with accumulation around transcriptional start sites. Interestingly, epigenetic effects of PADI4 on the bulk tumor cell population did not explain the CSC phenotype. However, in sorted tumor cell populations, PADI4 down-regulated expression of the master transcription factors of stemness, NANOG and POU5F1, specifically in the cancer stem cell compartment, by reducing the transcriptionally activating H3R17me2a histone mark at those loci. This effect was not seen in the non-stem cells. Our findings reveal a novel role for PADI4 as a tumor suppressor in regulating breast cancer stem cells, and provide insights into context-specific effects of PADI4 in epigenetic modulation.
Overall design Cells were cultured in DMEM/F12 media supplemented with 5% horse serum.
Cells were treated with PADI4 inhibitor (GSK484) or control compound (GSK107) for 72 hours.
Contributor(s) Moshkovich N, Ochoa HJ, Tang B, Yang HH, Yang Y, Huang J, Lee MP, Wakefield L
Citation(s) 32265227
Submission date Oct 03, 2019
Last update date Apr 12, 2021
Contact name Maxwell Lee
Phone 240-276-5239
Organization name National Cancer Institute, NIH
Department CCR
Lab Laboratory of Human Carcinogenesis
Street address Building 37, Room 5120
City Bethesda
State/province MD
ZIP/Postal code 20892
Country USA
Platforms (1)
GPL21290 Illumina HiSeq 3000 (Homo sapiens)
Samples (3)
GSM4107706 MCF10Ca1h cells, RNA.NT
GSM4107707 MCF10Ca1h cells, RNA.GSK484
GSM4107708 MCF10Ca1h cells, RNA.CON
This SubSeries is part of SuperSeries:
GSE138506 Peptidylarginine deiminase IV (PADI4) has a novel tumor cell-autonomous suppressor role in regulating breast cancer stem cells
BioProject PRJNA575771

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE138415_RAW.tar 4.0 Mb (http)(custom) TAR (of TXT)
Raw data are available in SRA
Processed data provided as supplementary file

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap